Medincell Stock Breaks Through €28.72 Resistance Ahead of Two US Conferences

An Acceleration that Extends a 26% Rally Over Three Months

Medincell gains 2.18% to €29.06, while the SBF 120 index is up 1.12% during the session. The stock extends its upward trajectory, with a 9.17% gain over the week and 26.13% over three months. Over one year, the performance reaches 76.87%. The stock's ranking in its reference index does not place it at the forefront of the session, but the orientation remains consistent with recent dynamics. The company announced on May 26 that its management will participate in two American biotech conferences in June, at a time when the group is progressing with its long-acting injectable treatments, with several candidates in clinical and commercial phases.

This communication follows a regulatory milestone achieved by the partnership with Teva, with the European Medicines Agency accepting the Olanzapine LAI file on May 22. This candidate, designed as a prolonged-release subcutaneous injection for the treatment of schizophrenia, is one of the most advanced in the biotech's technology portfolio.

A Price That Distinctly Moves Away from Its Three Moving Averages

At €29.06, the price moves above the €28.72 resistance identified in technical data. The RSI is at 65, close to the overbought zone without fully entering it, reflecting the strength of the movement without immediate reversal signals. The stock is trading with a positive gap of 8.92% above its MM20 (€26.68) and 19.24% above its MM50 (€24.37), confirming the bullish orientation in the short and medium term. The MM200 at €25.18 also remains below the current price, with a gap of 15.41%.

The one-month volatility is at 15.28, a level that remains contained given the magnitude of the recent progression. The crossing of the €28.72 zone, which had been targeted but missed in mid-May, opens a new graphical sequence beyond the previous ceiling. The two American conferences scheduled for June represent the next identified milestone for the company.